Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
IPO Year:
Exchange: AMEX
Website: daxor.com
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators. "We look forward to engaging with i
Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024. Event:Fireside Chat at 2024 Maxim Healthcare Virtual SummitDate:Tuesday, October 15, 2024Time:10:00 AM ETWebcast:https://m-vest.com/events/healthcare-10152024 Mr. Feldschuh will be available for one-on-one meetings with registered investors of the summit. Interested investors may also
Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. Food and Drug Administration (FDA), the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and resubmit a focused 510(k) application. This decision comes after considerable progress in addressing key regulatory considerations and aims to expedite the approval process, potentially bringing t
Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), taking place September 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta. The event will gather the world's top heart failure experts. Key meeting highlights: Exclusive showcase of BVA at the HFSA 'Devices in Heart Failure: From Mechanisms to Implementation' session.Presentation of products and services in the main Exhibit Hall.Corporate Member Meeting with HFSA leadership. "We're excited to showcase ho
Review Published in the Prestigious Journal Cardiorenal Medicine Oak Ridge, TN, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces a review published in the journal Cardiorenal Medicine that delves into the intricate landscape of cardiorenal syndrome (CRS) and highlights the pivotal role of Blood Volume Analysis (BVA) in improving patient care and outcomes. Key findings: BVA as a diagnostic tool enhances the precision of diuretic and red cell therapies, significantly elevating the effectiveness of conventional care.Integrating BVA in CRS care has clinical implications, including per
The SBIR Matching Fund Award Will Drive Our Innovation, Commercialization Efforts, and Job Creation Oak Ridge, TN, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces Launch Tennessee (LaunchTN) awarded Daxor Corporation a $300K SBIR matching fund to advance its next-generation point-of-care blood volume analyzer, building on Daxor's Phase II award from the Defense Health Agency. "This award is a welcome addition to Daxor's long-standing and robust portfolio of non-dilutive funding, which focuses on leveraging public funding to empower clinicians with advanced tools for optimal fluid management to en
1,000 Bed Comprehensive Medical Center Launches ezBVA Lab Program Oak Ridge, TN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. Daxor will partner with the hospital to provide lab processing of its patient tests, providing a rapid 24-hour testing service that is highly efficient for the hospital to implement. The hospital is a leading 1,000+ bed comprehensive medical center in western Florida aiming to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associa
Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting Daxor Corporation's remarkable progress and financial performance. Our commitment to innovation in blood volume analysis (BVA) technology continues to drive growth and create value for our stakeholders. Financial Highlights: I am thrilled to report that our financial position has strengthened signi
Oak Ridge, TN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 26th Annual Global Investment Conference being held on September 9-11, 2024 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning September 9, 2024 at 7:00 AM ET. Investors who wish to listen to the Company's presentation can do so by registering for the conference here: https://hcwevents.com/annualconference/ Mr. Feldschuh will be available for one-on-one meetings at the conference venue with registered
Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year. A rural 339-bed community hospital in northwest Mississippi, part of the Mid-South's largest integrated delivery network, has acquired a BVA analyzer for outpatient heart failure care. This acquisition is
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh
N-PX - DAXOR CORP (0000027367) (Filer)
N-CSRS - DAXOR CORP (0000027367) (Filer)
40-17G - DAXOR CORP (0000027367) (Filer)
N-2 - DAXOR CORP (0000027367) (Filer)
8-K - DAXOR CORP (0000027367) (Filer)
DEF 14A - DAXOR CORP (0000027367) (Filer)
8-K - DAXOR CORP (0000027367) (Filer)
NPORT-P - DAXOR CORP (0000027367) (Filer)
40-17F2 - DAXOR CORP (0000027367) (Subject)
40-17F2 - DAXOR CORP (0000027367) (Subject)
The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.
Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market PenetrationOak Ridge, TN, July 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA). This growth includes launching a BVA program and increasing adoption of Daxor's ezBVA Lab service - a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company foresees a strong lineup of developments in the second half of this year, reinforcing its trajectory of accelerated sales growth.Recent sales wins include:Regional referral center for Northeast A
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediat
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder:"Concentrate all your thoughts upon the work in hand. The sun's rays do not burn until brought to a focus." - Alexander Graham BellWe have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expa
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor's ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance. New client and services wins include:BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey.Daxor's ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio.Daxor's ezBVA Lab service extended to an academic, integrated health system locat
Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption Oak Ridge, TN, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor's ezBVA Lab service. These Q4 2023 initiatives have all played a significant role in driving the growth and the widespread adoption of BVA providing a strong position going into 2024.Q4-2023 sales wins include:BVA analyzer purchase at the largest and most integrated healthcare system in GeorgiaBVA analyzer purchase at a community-direct
This System Utilizes Unique Blood Volume Metrics And Related Clinical Measures To Create Support Guidance For Fluid Management Interventions
The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the BedsidePotential clearance is expected during the first half of 2024. The Company's mission is to advance healthcare by enabling optimal fluid management.
dxr
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base. Daxor projects the acquisitions to be cash flow positive and accretive to earnings imm
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Concentrate all your thoughts upon the work in hand. The sun's rays do not burn until brought to a focus." - Alexander Graham Bell We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume meas
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022. Management reported a NAV of $6.75 per share for fiscal 2022 versus $5.24 for the comparable period in 2021, a $1.51 increase or 36.95%, as well as a 20.5% increase in unaudited revenues and sales for its operating division, which produces and distributes its blood volume analysis (BVA) diagnostic systems and single use test kits which rose by 59.5%. "We a
Conference Call to be held at 9 AM EST March 2, 2023 Oak Ridge, TN, March 01, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, will report financial results for the full year ending December 31, 2022 on Wednesday, March 1, 2023 after the stock market close, and host a conference call on Thursday, March 2, 2023 at approximately 9:00 a.m. EST. President and CEO Michael Feldschuh and CFO Robert Michel will also host a conference call at 9:00 a.m. EST on Thursday, March 2, 2023 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answe
Conference Call to be held today at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2022. The increase in revenue of 92.6 percent in the Company's operating division represents strong strides in the commercialization of its BVA-100® Blood Volume Analyzer through a combination of the purchase and leasing of capital equipment, reference lab use, and the opening of twelve new commercial and academic accounts, along with a 9.2 percent price increase that was well rece
Conference Call to be held on the same day at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, will report financial results for the six months ending June 30, 2022, on Thursday, August 25, 2022 at approximately 4:00 p.m. Eastern Time. President and CEO President Michael Feldschuh and CFO Robert Michel will also host an earnings conference call at 4:30 p.m. ET on Thursday, August 25, 2022, to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and- answer session. Investors are invited to sub
TORONTO, Aug. 19, 2021 /CNW/ - Dynamic Funds today announced the August 2021 cash distribution for Dynamic Active Retirement Income+ ETF (AMEX:DXR) listed on the TSX, which pays on a monthly basis. Unitholders of record on August 26, 2021 will receive a cash distribution of $0.083 per unit on August 31, 2021. Dynamic Active International Dividend ETF (TICKER:DXW) will not pay a cash distribution this month. For more information about these and the other Dynamic Active ETFs, please visit Dynamic.ca/ETF. Commissions, management fees and expenses all may be associated with inve